MedTrace Logo

Long-term Extension Study of BEMA™ Fentanyl

NCT00696137 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-09-24

Study results available
· View outcomes & findings →

Summary

This study is designed to provide continued access to BEMA Fentanyl for those subjects who previously participated in FEN-202 and who wish to continue using BEMA Fentanyl for the treatment of their breakthrough cancer pain.

Conditions

  • Respiratory Depression

Interventions

DRUG

BEMA Fentanyl

buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily

Sponsors & Collaborators

  • BioDelivery Sciences International

    lead INDUSTRY

Principal Investigators

  • David Blum, MD · BioDelivery Sciences International

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-07-31
Completion
2009-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00696137 on ClinicalTrials.gov